SCHEMBL14185084

SCHEMBL14185084

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3c(OCCN4CCOCC4)cccc23)cc1

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 10/20 0.91
▸ TNF P01375 7/20 0.91
▸ MAPK13 O15264 3/20 0.91
▸ MAPK12 P53778 3/20 0.91
▸ MAPK11 Q15759 3/20 0.91
▸ DDR2 Q16832 3/20 0.91
▸ CIT O14578 1/20 0.91
▸ MUSK O15146 1/20 0.91
▸ MAP3K7 O43318 1/20 0.91
▸ RIPK2 O43353 1/20 0.91
▸ STK10 O94804 1/20 0.91
▸ MAP4K4 O95819 1/20 0.91
▸ CHEK2 O96017 1/20 0.91
▸ ABL1 P00519 1/20 0.91
▸ EGFR P00533 1/20 0.91
▸ RAF1 P04049 1/20 0.91
▸ NTRK1 P04629 1/20 0.91
▸ HSPB1 P04792 1/20 0.91
▸ PRKCB P05771 1/20 0.91
▸ LCK P06239 1/20 0.91

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doramapimod SCHEMBL29353023 0.95 MAPK14 (1.00) MAPK14TNFMAPK13MAPK12MAPK11
Doramapimod SCHEMBL129721 0.95 MAPK14 (1.00) MAPK14TNFMAPK13MAPK12MAPK11
Doramapimod SCHEMBL10320344 0.95 MAPK14 (0.98) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL20876996 0.92 MAPK14 (0.93) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL6330722 0.91 MAPK14 (1.00) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL295302 0.90 MAPK14 (1.00) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL5967533 0.90 MAPK14 (0.89) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL295792 0.89 MAPK14 (0.89) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL13857350 0.89 MAPK14 (0.89) MAPK14TNFMAPK13MAPK12MAPK11
SCHEMBL29594033 0.89 MAPK14 (0.89) MAPK14TNFMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885TNF 677/4885MAPK13 15/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885TNF 237/4885MAPK13 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback